What is the 13F Pro Quality Score for HRMY?

13F Pro ranks Harmony Biosciences Holdings, Inc. (HRMY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HRMY's current score at https://13fpro.ai/research/HRMY (free sign-up required for the full ranking).

Which hedge funds own the most HRMY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HRMY include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/HRMY as soon as new 13F filings post.

Where does 13F Pro source HRMY data?

All Harmony Biosciences Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Harmony Biosciences Holdings, Inc. files with the SEC under CIK 1802665. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HRMY in?

Harmony Biosciences Holdings, Inc. (HRMY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives HRMY's revenue?

Per Harmony Biosciences Holdings, Inc.'s latest 10-Q filed with the SEC on 2026-05-07, the biggest revenue drivers are: WAKIX (pitolisant) - narcolepsy and sleep disorders ($215.4M, +16.6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/HRMY.

What are HRMY's largest expenses?

Harmony Biosciences Holdings, Inc.'s latest 10-Q reports these as the largest expense items: Research and development ($69.4M, +100.9% YoY); Cost of product sold ($44.5M, +39.1% YoY); Sales and marketing ($31.7M, +3.2% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is HRMY research updated on 13F Pro?

HRMY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Harmony Biosciences Holdings, Inc.(HRMY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1802665 HRMY stock profile & AI dashboard →

13F Pro Quality Score

75.3/100

Rank #132 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

82.0/100

Profitability

83.7/100

Balance Sheet

91.4/100

Earnings Quality

54.5/100

Free Cash Flow

85.7/100

Institutional Flow

93.4/100

Revenue Scale

46.1/100

Dilution Risk

25.4/100

HRMY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Harmony Biosciences Holdings, Inc. (HRMY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HRMY at 75.3/100 on a 32-signal composite quality model, placing it at rank #132 of 2,879 stocks — the top 5% of the AI-ranked universe. HRMY scores in the top quartile across institutional flow (93.4), balance sheet strength (91.4), free cash flow (85.7). Shareholder dilution risk is elevated at 25.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Harmony Biosciences Holdings, Inc. reports quarterly revenue of $215.4M, net income of $32.5M, an operating margin of 17.3%. Top institutional holders of HRMY by reported 13-F value include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HRMY trades on the Nasdaq exchange and files with the SEC under CIK 1802665. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HRMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Harmony Biosciences Holdings, Inc. directly from SEC EDGAR. Harmony Biosciences Holdings, Inc.'s 13F Pro composite quality score has ranged between 41 and 83 since 2021, currently 75.3 — an improving long-term trajectory across 29 quarterly and live scoring snapshots.

✦

Fun facts about Harmony Biosciences Holdings, Inc.

Quirks, history, and lore behind HRMY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a portfolio built around a single core therapeutic area — a high-risk, high-focus strategy.
3
The History
Founded in 2017 and went public in 2020, making it one of the younger publicly traded pharma companies — barely old enough to vote, already selling prescription drugs.
4
The Secret
The entire business is laser-focused on sleep and wake disorders — conditions that affect tens of millions of Americans but have historically been underserved by drug development.
5
The Lore
Its flagship drug targets excessive daytime sleepiness associated with narcolepsy, competing in a niche where patients have long had few good options — and the company bet everything on it.
6
The Giveaway
The name itself promises peaceful rest: a neuroscience-focused pharma company whose lead product Wakix (pitolisant) was the first narcolepsy treatment with a novel mechanism approved in decades.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving HRMY's Business? Latest 10-Q Breakdown

AI-extracted from Harmony Biosciences Holdings, Inc.'s 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

HRMY reported Q1 2026 revenue of $215.4M (+16.6% YoY) driven by 12.1% unit growth in WAKIX, but R&D expenses surged 101% to $69.4M due to $32M in upfront IPR&D payments for new license agreements.

Biggest Revenue Drivers

Total revenue: $215.4M+16.6% YoY

WAKIX (pitolisant) - narcolepsy and sleep disorders$215.4M+16.6% YoY

12.1% increase in units shipped plus 7% price increase (January 2026) partially offset by higher rebates (~3.7%).

Largest Expense Items

Research and development$69.4M+100.9% YoY

$32.0M IPR&D charges (Novitium $15M, MSN $17M license upfronts), plus $7.4M increase in EPX-100 and Pitolisant GR/HD development costs.

Cost of product sold$44.5M+39.1% YoY

Higher royalties from revenue growth and new royalties under Novitium License Agreement; cost of product sold as percentage of revenue increased to 20.7% from 17.3%.

Sales and marketing$31.7M+3.2% YoY

$2.6M increase in patient engagement and marketing activities and $0.5M higher personnel costs.

General and administrative$32.5M+4.0% YoY

$2.3M increase in legal and professional fees primarily for patent litigation; $0.3M higher personnel costs.

Watch Items from the Filing

Three customers represent 100% of Q1 2026 product revenue: CVS Caremark 37%, Accredo 36%, PANTHERx 27%. High concentration risk with specialty pharmacy distribution.
Company had event of default on TLA Credit Agreement (dated July 2025) related to subsidiary guarantee covenant delay; waived May 4, 2026. All principal/interest payments current as of May 7, 2026.
Significant ANDA litigation pipeline: Lupin, Novugen, Hikma, AET, and others settled to allow generic entry July 2030 or earlier if WAKIX loses pediatric exclusivity; MSN settlement terms remain confidential.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$215.4M

Net Income

Q1 2026

$32.5M

Free Cash Flow

Q1 2026

$27.8M

Operating Margin

Q1 2026

17.3%

D/E Ratio

Q1 2026

0.20

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+21.5% YoY

$868.5MFY 2025

FY22 $437.9MFY23 $582.0MFY24 $714.7MFY25 $868.5M

Net Income

+9.1% YoY

$158.7MFY 2025

FY22 $181.5MFY23 $128.9MFY24 $145.5MFY25 $158.7M

Operating Income

+9.2% YoY

$208.5MFY 2025

FY22 $120.2MFY23 $192.0MFY24 $190.8MFY25 $208.5M

EPS (Diluted)

+8.0% YoY

$2.71FY 2025

FY22 $2.97FY23 $2.13FY24 $2.51FY25 $2.71

Total Assets

+27.3% YoY

$1.27BFY 2025

FY22 $673.9MFY23 $811.4MFY24 $999.2MFY25 $1.27B

Total Debt

-6.1% YoY

$183.7MFY 2025

FY22 $193.6MFY23 $208.6MFY24 $195.5MFY25 $183.7M

Op. Cash Flow

+58.4% YoY

$348.2MFY 2025

FY22 $144.5MFY23 $219.4MFY24 $219.8MFY25 $348.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$868.5M +21.5%	$714.7M +22.8%	$582.0M +32.9%	$437.9M +43.4%	$305.4M +91.2%	$159.7M
Net Income	$158.7M +9.1%	$145.5M +12.9%	$128.9M -29.0%	$181.5M +424.5%	$34.6M +193.6%	$-36.9M
Operating Income	$208.5M +9.2%	$190.8M -0.6%	$192.0M +59.8%	$120.2M +37.3%	$87.5M +415.3%	$17.0M
EPS (Diluted)	$2.71 +8.0%	$2.51 +17.8%	$2.13 -28.3%	$2.97 +412.1%	$0.58 +123.4%	$-2.48
Total Assets	$1.27B +27.3%	$999.2M +23.1%	$811.4M +20.4%	$673.9M +55.5%	$433.4M +1.5%	$427.1M
Total Debt	$183.7M -6.1%	$195.5M -6.3%	$208.6M +7.7%	$193.6M -0.2%	$194.0M -0.1%	$194.3M
Operating Cash Flow	$348.2M +58.4%	$219.8M +0.2%	$219.4M +51.9%	$144.5M +46.6%	$98.6M +3401.7%	$-3.0M

Get alerted when HRMY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Harmony Biosciences Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HRMY

BlackRock, Inc.
$198.0M7,070,035 sh
FMR LLC
$88.4M3,157,639 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$76.0M2,714,353 sh
AMERICAN CENTURY COMPANIES INC
$59.0M2,105,179 sh
VANGUARD CAPITAL MANAGEMENT LLC
$58.9M2,102,315 sh
DIMENSIONAL FUND ADVISORS LP
$58.2M2,076,510 sh
STATE STREET CORP
$50.0M1,784,362 sh
ARMISTICE CAPITAL, LLC
$45.5M1,624,000 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$38.7M1,382,113 sh
GEODE CAPITAL MANAGEMENT, LLC
$37.1M1,322,720 sh

Fund	Value	Shares
BlackRock, Inc.	$198.0M	7,070,035
FMR LLC	$88.4M	3,157,639
VANGUARD PORTFOLIO MANAGEMENT LLC	$76.0M	2,714,353
AMERICAN CENTURY COMPANIES INC	$59.0M	2,105,179
VANGUARD CAPITAL MANAGEMENT LLC	$58.9M	2,102,315
DIMENSIONAL FUND ADVISORS LP	$58.2M	2,076,510
STATE STREET CORP	$50.0M	1,784,362
ARMISTICE CAPITAL, LLC	$45.5M	1,624,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$38.7M	1,382,113
GEODE CAPITAL MANAGEMENT, LLC	$37.1M	1,322,720

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HRMY on your watchlist

Track score changes the day Harmony Biosciences Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HRMY a good stock to buy?

13F Pro's AI-powered analysis of Harmony Biosciences Holdings, Inc. (HRMY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HRMY are available on the HRMY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HRMY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HRMY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Harmony Biosciences Holdings, Inc.'s investment landscape.